# Clinical utility of CLL-IPI scoring system in Pakistani Chronic Lymphocytic Patients: A single center experience

## TL;DR

This study evaluated the CLL-IPI scoring system in Pakistani patients with chronic lymphocytic leukemia and found it did not reliably predict survival outcomes in this population.

## Contribution

The study provides insights into the applicability of the CLL-IPI scoring system in a Pakistani patient cohort, highlighting its limitations in this specific population.

## Key findings

- The CLL-IPI classification did not show significant differences in overall survival among risk groups.
- The median overall survival for the very high-risk group was only six months.
- A larger sample size is needed to validate the CLL-IPI system in this population.

## Abstract

To determine validity of the CLL International prognostic index (IPI) scoring system in Pakistani chronic lymphocytic leukemia patients, as the validity and universal applicability of various prognostic scoring systems such as the CLL-IPI remains a challenge, particularly in under-developed countries like Pakistan.

This prospective single center study was conducted at Department of Hematology, University of Health Sciences, Lahore and included sixty patients with CLL diagnosed between July, 2019 to July, 2022. Patients were followed for a period of two years and 02 year overall survival (OS) was noted. Risk stratification was conducted according to CLL-IPI prognostic model.

Among 60 patients, the mean age was 60±11years. Advanced Binet stage B+C and elevated β2-microglobulin >3.5mg/L was observed in 73.3% and 38.3% patients respectively. The estimated median 02 years OS was 16.5 months (95% CI: 10-20 months). In total, 40 of 60 CLL patients (67%) were accessible for follow-up analyses. For the present CLL cohort, 25% patients (n = 10) were classified as CLL-IPI low risk and intermediate risk group, 35% (n = 14) as high risk and 15% (n = 06) as very high-risk group. However, this classification of patients according to CLL-IPI did not yield significant differences in terms of OS (p = 0.24), although the median OS of CLL-IPI very high-risk group was noted as only six months and was not reached for low and intermediate risk groups.

To conclude, clinical validation of CLL-IPI scoring system could not be established for the present CLL cohort and needs to be evaluated in further studies with larger sample size.